Skip to content

Eton Pharmaceutical

US · ETON #2944 by market cap Listed 2018
60.85 -0.51 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 45 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.3 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
74.21% +2.29pp
Institutions
233 +45
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund37.70%
Hedge Fund29.53%
Individual/Insider4.88%
Public Company3.42%
Private Company1.32%
Insurance Company1.11%
Sovereign Wealth Fund0.66%
Government Pension Fund0.38%
Other20.91%

Top holders as of 2026-09-30

Opaleye Management Inc. 8.46% · 2.44M sh
EcoR1 Capital, LLC 7.53% · 2.17M sh
BlackRock 7.27% · 2.10M sh
Vanguard Capital Management, LLC 4.17% · 1.20M sh
Nantahala Capital Management, LLC 4.08% · 1.18M sh
Sean Brynjelsen 3.33% · 961.19K sh
FMR 2.86% · 823.45K sh
Morgan Stanley 2.63% · 751.03K sh
State Street Global Advisors 2.69% · 775.54K sh
Geode Capital Management, LLC 2.65% · 764.40K sh
Oberweis Asset Management, Inc. 1.75% · 501.60K sh
Morgan Stanley Investment Management Inc. 1.78% · 513.17K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 21 sells

NameRoleStake
Sean Brynjelsen Chief Executive Officer 3.33%
Norbert Riedel Independent Chairperson 0.78%
Paul Maier Independent Director 0.25%
Charles Casamento Independent Director 0.24%
David Krempa Chief Business Officer 0.15%
Danka Radosavljevic Chief Operating Officer 0.08%
James Gruber Consultant 0.06%
Ipek Erdogan-Trinkaus Chief Commercial Officer 0.00%
Opaleye Management Inc. -- --
Jennifer Adams Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Charles Casamento Independent Director Derivative Exercise and Sale -80,555 $3.58–67.87
2026-11-09 Ipek Erdogan-Trinkaus Chief Commercial Officer Derivative Exercise and Sale -3,500 $15.47–67.88
2026-10-05 David Krempa Chief Business Officer Derivative Exercise and Sale -4,166 $55.07
2026-10-05 David Krempa Chief Business Officer Intent to Sell (Form 144) -4,166 $55.07
2026-10-01 David Krempa Chief Business Officer Derivative Exercise and Retained +6,356 --
2026-08-27 Paul Maier Independent Director Derivative Exercise and Sale -50,000 $3.78–61.77
2026-08-27 Paul Maier Independent Director Other Derivative Acquisition +12,500 $7.31
2026-08-27 Paul Maier Independent Director Derivative Exercise and Retained +12,500 $7.31
2026-08-23 David Krempa Chief Business Officer Derivative Exercise and Sale -25,000 $7.31–65.07
2026-08-19 Sean Brynjelsen Chief Executive Officer Open Market Disposition -100,000 $60.17–62.65
2026-08-18 Sean Brynjelsen Chief Executive Officer Intent to Sell (Form 144) -100,000 $63.43
2026-07-30 Paul Maier Independent Director Other Derivative Acquisition +10,000 --
2026-07-30 Charles Casamento Independent Director Other Derivative Acquisition +10,000 --
2026-07-30 Norbert Riedel Independent Chairperson Other Derivative Acquisition +10,000 --
2026-07-30 David Krempa Chief Business Officer Other Derivative Acquisition +128,985 --
2026-07-30 Jennifer Adams Independent Director Other Derivative Acquisition +10,000 --
2026-07-30 Judith Matthews Chief Financial Officer & Secretary Other Derivative Acquisition +32,246 --
2026-07-30 Danka Radosavljevic Chief Operating Officer Initial Statement of Beneficial 0 --
2026-07-30 Ipek Erdogan-Trinkaus Chief Commercial Officer Other Derivative Acquisition +80,000 --
2026-07-13 Opaleye Management Inc. -- Open Market Disposition -28,315 $37.54

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Eton Pharmaceutical discussion 0 comments

Add a comment